Fusion Antibodies PLC (FAB) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.792x

Based on the latest financial reports, Fusion Antibodies PLC (FAB) has a cash flow conversion efficiency ratio of -0.792x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-575.00K ≈ $-69.96 USD) by net assets (GBX726.00K ≈ $88.33 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Fusion Antibodies PLC defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Fusion Antibodies PLC - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Fusion Antibodies PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Fusion Antibodies PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Fusion Antibodies PLC ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Captivision Inc NASDAQ:CAPT	0.085x
ImagineAR Inc F:GMS1	0.046x
Kalium Lakes Ltd AU:KLL	0.761x
Virgin Wines UK PLC LSE:VINO	-0.137x
HAVN LIFE SCIENCES INC. F:5NP0	N/A
Aptamer Group PLC LSE:APTA	-0.493x
Northern Bear Plc LSE:NTBR	0.121x
Haydale Graphene Industries LSE:HAYD	-0.398x

Annual Cash Flow Conversion Efficiency for Fusion Antibodies PLC (2015–2025)

The table below shows the annual cash flow conversion efficiency of Fusion Antibodies PLC from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Fusion Antibodies PLC.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	GBX669.00K ≈ $81.40	GBX-1.36 Million ≈ $-165.96	-2.039x	-106.65%
2024-03-31	GBX1.79 Million ≈ $218.16	GBX-1.77 Million ≈ $-215.24	-0.987x	+36.87%
2023-03-31	GBX1.12 Million ≈ $136.64	GBX-1.75 Million ≈ $-213.53	-1.563x	-1644.63%
2022-03-31	GBX3.68 Million ≈ $448.24	GBX-330.00K ≈ $-40.15	-0.090x	+63.06%
2021-03-31	GBX4.75 Million ≈ $577.57	GBX-1.15 Million ≈ $-140.04	-0.242x	-602.87%
2020-03-31	GBX4.81 Million ≈ $585.48	GBX-166.00K ≈ $-20.20	-0.034x	+83.18%
2019-03-31	GBX5.35 Million ≈ $651.44	GBX-1.10 Million ≈ $-133.64	-0.205x	-1847.36%
2018-03-31	GBX6.58 Million ≈ $800.00	GBX77.19K ≈ $9.39	0.012x	+153.59%
2017-03-31	GBX1.71 Million ≈ $207.56	GBX-37.37K ≈ $-4.55	-0.022x	-109.21%
2016-03-31	GBX1.46 Million ≈ $177.28	GBX346.57K ≈ $42.17	0.238x	+122.12%
2015-03-31	GBX169.29K ≈ $20.60	GBX-182.05K ≈ $-22.15	-1.075x	--

About Fusion Antibodies PLC

LSE:FAB UK Biotechnology

Market Cap

$172.86K

GBX1.42 Billion GBX

Market Cap Rank

#31153 Global

#1038 in UK

Share Price

GBX12.50

Change (1 day)

+4.17%

52-Week Range

GBX6.15 - GBX19.25

All Time High

GBX213.00